Neurim Pharmaceuticals (1991) Ltd & Anor v Generics UK Ltd & Anor
Since the interim injunction was refused on the basis that damages were an adequate remedy, and not on the merits, costs should not be reserved but awarded now, with Mylan recovering 65% of its assessed costs to reflect the issues lost.
- Parties
- Claimant: Neurim Pharmaceuticals (1991) Limited; Claimant: Flynn Pharma Limited; Defendant: Generics UK Limited (trading as Mylan); Defendant: Mylan UK Healthcare Limited
- Jurisdiction
- England and Wales
- Judgment Date
- 08 June 2020
- Procedural Posture
- Patent Litigation / Costs Ruling Following Refusal of Interim Injunction
- Outcome
- Application for costs by Mylan granted in part
- Legal Topics
- Interim Injunctions, Costs, Patents
Case Brief
Summary, issues, holding and outcome
More case intelligence is available
Unlock the full research layer for this judgment.
Parties
Neurim Pharmaceuticals (1991) Limited
Claimant
Flynn Pharma Limited
Claimant
Generics UK Limited (trading as Mylan)
Defendant
Mylan UK Healthcare Limited
Defendant
Procedural Posture
Patent Litigation / Costs Ruling Following Refusal of Interim Injunction
Legal Issues
- 1 Whether costs should be reserved or awarded after refusal of interim injunction
- 2 Appropriate proportion of costs to be awarded to the successful party
Ratio Decidendi
Since the interim injunction was refused on the basis that damages were an adequate remedy, and not on the merits, costs should not be reserved but awarded now, with Mylan recovering 65% of its assessed costs to reflect the issues lost.
Court Disposition
Application for costs by Mylan granted in part
Orders
- Mylan to recover 65% of its assessed costs, subject to detailed assessment if not agreed
- Payment on account of costs in the amount of £80,000 ordered
Full Case Text
Judgment text and source record
Sign in to read
Sign in to read the full judgment text
Sign in to read the full judgment text. Downloads and additional research tools may depend on your plan.
Sign in to read the full judgment